Cargando…

Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study

A wide variety of coils are available for vascular embolization. This study aimed to evaluate the safety and efficacy of a new Prestige coil. We carried out retrospective analysis of a multicenter’s registry data collected between February 2022 and November 2022. The choice of embolization agent use...

Descripción completa

Detalles Bibliográficos
Autores principales: Frandon, Julien, Loffroy, Romaric, Marcelin, Clement, Vernhet-Kovacsik, Hélène, Greffier, Joel, Dabli, Djamel, Sammoud, Skander, Marek, Pierre, Chevallier, Olivier, Beregi, Jean-Paul, Rousseau, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608704/
https://www.ncbi.nlm.nih.gov/pubmed/37888075
http://dx.doi.org/10.3390/jpm13101464
_version_ 1785127843338911744
author Frandon, Julien
Loffroy, Romaric
Marcelin, Clement
Vernhet-Kovacsik, Hélène
Greffier, Joel
Dabli, Djamel
Sammoud, Skander
Marek, Pierre
Chevallier, Olivier
Beregi, Jean-Paul
Rousseau, Hervé
author_facet Frandon, Julien
Loffroy, Romaric
Marcelin, Clement
Vernhet-Kovacsik, Hélène
Greffier, Joel
Dabli, Djamel
Sammoud, Skander
Marek, Pierre
Chevallier, Olivier
Beregi, Jean-Paul
Rousseau, Hervé
author_sort Frandon, Julien
collection PubMed
description A wide variety of coils are available for vascular embolization. This study aimed to evaluate the safety and efficacy of a new Prestige coil. We carried out retrospective analysis of a multicenter’s registry data collected between February 2022 and November 2022. The choice of embolization agent used to treat peripheral vascular anomalies was left to the investigator’s discretion. Patients for whom at least one Prestige coil was used were included in Series 1. All other patients were included in Series 2. Efficacy and safety were evaluated. Patients were followed up for one month. In total, 220 patients were included, 110 in each series. Patients included 149 men (67.7%) and 71 women (32.3%), with a median age of 62.5 years (IQR: 35.8–73). Patient ages were similar in the two series. Complete occlusion of the targeted vessel was reported in 96.4% (n = 106/110) of patients in Series 1 and in 99.7% (n = 109/110) in Series 2. Four patients experienced non-serious adverse events (1.8%, n = 4/220): one experienced back pain and one vomiting in Series 1; one patient had off-target embolization and one a puncture site hematoma in Series 2. Sixteen patients (7.2%, n = 16/220) were lost to follow up. Improvement in the patient’s general state at one month was reported in 79.0% (n = 83/105) of patients in Series 1 and in 74.7% (n = 74/99) in Series 2. Ten deaths occurred, five in Series 1 (4.8%, n = 5/105) and five in Series 2 (5.1%, n = 5/99). These deaths all concerned critically ill patients embolized for emergent arterial bleeding. In conclusion, the 1-month follow-up showed that Prestige coils, alone or in combination, are efficient and safe.
format Online
Article
Text
id pubmed-10608704
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106087042023-10-28 Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study Frandon, Julien Loffroy, Romaric Marcelin, Clement Vernhet-Kovacsik, Hélène Greffier, Joel Dabli, Djamel Sammoud, Skander Marek, Pierre Chevallier, Olivier Beregi, Jean-Paul Rousseau, Hervé J Pers Med Article A wide variety of coils are available for vascular embolization. This study aimed to evaluate the safety and efficacy of a new Prestige coil. We carried out retrospective analysis of a multicenter’s registry data collected between February 2022 and November 2022. The choice of embolization agent used to treat peripheral vascular anomalies was left to the investigator’s discretion. Patients for whom at least one Prestige coil was used were included in Series 1. All other patients were included in Series 2. Efficacy and safety were evaluated. Patients were followed up for one month. In total, 220 patients were included, 110 in each series. Patients included 149 men (67.7%) and 71 women (32.3%), with a median age of 62.5 years (IQR: 35.8–73). Patient ages were similar in the two series. Complete occlusion of the targeted vessel was reported in 96.4% (n = 106/110) of patients in Series 1 and in 99.7% (n = 109/110) in Series 2. Four patients experienced non-serious adverse events (1.8%, n = 4/220): one experienced back pain and one vomiting in Series 1; one patient had off-target embolization and one a puncture site hematoma in Series 2. Sixteen patients (7.2%, n = 16/220) were lost to follow up. Improvement in the patient’s general state at one month was reported in 79.0% (n = 83/105) of patients in Series 1 and in 74.7% (n = 74/99) in Series 2. Ten deaths occurred, five in Series 1 (4.8%, n = 5/105) and five in Series 2 (5.1%, n = 5/99). These deaths all concerned critically ill patients embolized for emergent arterial bleeding. In conclusion, the 1-month follow-up showed that Prestige coils, alone or in combination, are efficient and safe. MDPI 2023-10-05 /pmc/articles/PMC10608704/ /pubmed/37888075 http://dx.doi.org/10.3390/jpm13101464 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Frandon, Julien
Loffroy, Romaric
Marcelin, Clement
Vernhet-Kovacsik, Hélène
Greffier, Joel
Dabli, Djamel
Sammoud, Skander
Marek, Pierre
Chevallier, Olivier
Beregi, Jean-Paul
Rousseau, Hervé
Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
title Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
title_full Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
title_fullStr Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
title_full_unstemmed Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
title_short Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
title_sort safety and efficacy of prestige coils for embolization of vascular abnormalities: the embo-prestige study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608704/
https://www.ncbi.nlm.nih.gov/pubmed/37888075
http://dx.doi.org/10.3390/jpm13101464
work_keys_str_mv AT frandonjulien safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT loffroyromaric safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT marcelinclement safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT vernhetkovacsikhelene safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT greffierjoel safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT dablidjamel safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT sammoudskander safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT marekpierre safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT chevallierolivier safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT beregijeanpaul safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy
AT rousseauherve safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy